Sutro Biopharma Price to Sales Ratio 2017-2021 | STRO

Historical PS ratio values for Sutro Biopharma (STRO) over the last 10 years. The current P/S ratio for Sutro Biopharma as of January 19, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Sutro Biopharma P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-01-20 9.99 7.31
2021-09-30 18.89 $1.37 13.83
2021-06-30 18.59 $1.65 11.25
2021-03-31 22.76 $1.34 16.96
2020-12-31 21.71 $1.33 16.31
2020-09-30 10.05 $1.57 6.40
2020-06-30 7.76 $1.63 4.75
2020-03-31 10.20 $1.79 5.68
2019-12-31 11.00 $1.86 5.90
2019-09-30 9.09 $4.69 1.94
2019-06-30 11.38 $20.41 0.56
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.480B $0.043B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.655B 9.08
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.351B 19.22
Biohaven Pharmaceutical Holding (BHVN) United States $7.535B 0.00
Emergent Biosolutions (EBS) United States $2.453B 8.82
Arcus Biosciences (RCUS) United States $2.353B 0.00
Myovant Sciences (MYOV) United Kingdom $1.344B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.156B 0.00
Zymeworks (ZYME) Canada $0.627B 0.00
Ambrx Biopharma (AMAM) United States $0.207B 0.00
SQZ Biotechnologies (SQZ) United States $0.207B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81